Regeneron Pharmaceuticals Inc. buy Jefferies Financial Group Inc.
Start price
27.08.25
/
50%
€513.20
Target price
27.08.26
€714.24
Performance (%)
23.28%
Price
16.01.26
€631.80
Summary
This prediction is currently active. The BUY prediction by Jefferies_Financial_ currently has a performance of 23.28%. A total of €0.88 was paid as dividends for this prediction. This prediction currently runs until 27.08.26. The prediction end date can be changed by Jefferies_Financial_ at any time. Jefferies_Financial_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | -7.713% | -7.713% |
| iShares Core DAX® | 0.191% | 4.892% |
| iShares Nasdaq 100 | -0.614% | 2.901% |
| iShares Nikkei 225® | 0.599% | 7.404% |
| iShares S&P 500 | -0.036% | 3.489% |
Comments by Jefferies_Financial_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Jefferies Financial Group Inc. from $813.00 to $831.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Stopped prediction by Jefferies_Financial_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€729.00
28.11.23
28.11.23
€852.48
28.11.24
28.11.24
-2.41%
29.11.24
29.11.24
